Sulthiame - Desitin Arzneimittel GmbH
Alternative Names: Ospolot; Sulthiame; Sultia; SultiameLatest Information Update: 01 Jul 2024
Price :
$50 *
At a glance
- Originator Desitin Pharmaceuticals GmbH
- Class Antiepileptic drugs; Benzene derivatives; Sleep disorder therapies; Small molecules; Sulfonamides; Thiazines
- Mechanism of Action Carbonic anhydrase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Sleep apnoea syndrome
Most Recent Events
- 17 May 2024 Efficacy and adverse event data from a phase II trial in Sleep apnoea syndrome presented at 120th International Conference of the American Thoracic Society (ATS-2024)
- 31 Aug 2023 Desitin Arzneimittel GmbH completes phase-II trial in Sleep apnoea syndrome in Belgium, Germany, Czech Republic, France and Spain (PO) (EudraCT2021-002926-26) (NCT05236842)
- 04 Sep 2022 Updated efficacy data from a phase IIb trial in Sleep apnoea syndrome presented at the 32nd Annual Congress of the European Respiratory Society (ERS-2022)